Supplemental Drug Approvals Without Clinical Trials Under Congressional Consideration
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
House Energy and Commerce Committee seeks ideas for restructuring FDA to accelerate approvals and maintain U.S. health innovation dominance in the 21st century.
You may also be interested in...
From Trial Hold To Post-EUA Surveillance: FDA Wants J&J To Monitor COVID-19 Vaccine Data For Clots
Safety data does not look to be a barrier J&J vaccine’s authorization, but FDA says it will recommend surveillance for further evaluation of thromboembolic events. The agency says it currently cannot rule out a causal relationship with the vaccine. One of these cases prompted a study hold last fall.
FDA Commissioner Race: Biden Team Trying To Woo Reluctant Dems On Woodcock While Exploring New Options
The White House is trying to overcome some Senate Democrats’ opposition to Janet Woodcock as US FDA commissioner, while also looking for other candidates for the job. Josh Sharfstein, long thought to be Woodcock’s main competition, is not a strong contender.
US FDA Commissioner Race Shrinks And Widens: Biden Team Trying To Woo Reluctant Dems On Woodcock While Exploring New Options
White House is trying to overcome some Senate Democrats’ opposition to Janet Woodcock as FDA Commissioner, while also looking for other candidates for the job. Josh Sharfstein, long thought to be Woodcock’s main competition, is not a strong contender.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: